Isoxanthopterin (Synonyms: NSC 118090,NSC 614991) |
Catalog No.GC10834
One-Click Copy Product Info
|
interferes with RNA and DNA synthesis
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 529-69-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Isoxanthopterin interferes with RNA and DNA synthesis.
Isoxanthopterin, a natural intermediate in the pteridine pathway, plays critical roles in pigmentation and cell division.
In vitro: Isoxanthopterin was identified as a pteridine of wide natural occurrence and was reported to exerts an inhibitory action on the synthesis of ribosomal RNA, possibly soluble RNA and on DNA in developing eggs of the milkweed bug Oncopeltus fasciatus. Such effects were measured by partially incubating dechorionated eggs in a solution containing isoxanthopterin and radioactive uridine or thymidine, and then testing the incorporation of the isotope into ribosomal RNA or DNA. The detailed mechanism of this inhibition had been discussed, and the tentative conclusion was agreed that it was due to an interaction between the pteridine and the nucleic acid (most probably DNA) [1].
In vivo: Previous animal study showed that rats with inherited retinal dystrophy appeared to differ from healthy rats by an elevated isoxanthopterin excretion in urine. RCS rats responded to feeding of monapterin with an increase of isoxanthopterin excretion. This phenomenon supported the idea that the RCS rat had an increased xanthinoxidase activity compared with healthy rats [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Lagowski, J. M. and Forrest, H.S. Interaction in vitro between isoxanthopterin and DNA. Proceedings of the National Academy of Sciences of the United States of America 58(4), 1541-1547 (1967).
[2] G. Cremer-Bartels, H. Gerding, L. Hanneken and K. Krause. Isoxanthopterin Excretion of Rats with Inherited Retinal Dystrophy. Pteridines Vol. 2, 1990, pp. 103 -105.
| Cas No. | 529-69-1 | SDF | |
| Synonyms | NSC 118090,NSC 614991 | ||
| Chemical Name | 2-amino-4,7(3H,8H)-pteridinedione | ||
| Canonical SMILES | O=C1C=NC(C(N=C(N)N2)=O)=C2N1 | ||
| Formula | C6H5N5O2 | M.Wt | 179.1 |
| Solubility | ≤5mg/L in Water | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 5.5835 mL | 27.9174 mL | 55.8347 mL |
| 5 mM | 1.1167 mL | 5.5835 mL | 11.1669 mL |
| 10 mM | 558.3 μL | 2.7917 mL | 5.5835 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)